In the final stages of ALS, progressive motor neuron loss reaches the muscles that control breathing, swallowing, and communication, making respiratory failure the leading cause of death. But the path to that endpoint involves a constellation of changes that go well beyond the loss of movement most people associate with the disease. Cognitive shifts, autonomic dysfunction, pain, metabolic changes, and difficult decisions about ventilation and palliative care all converge in ways that patients, families, and caregivers rarely anticipate.
Respiratory Failure Is the Central Event
The diaphragm and the muscles between the ribs are what drive each breath. As motor neurons supplying these muscles die off, the diaphragm weakens progressively. Early on, this shows up as breathlessness during exertion, but eventually it impairs breathing even at rest. The earliest sign of serious trouble is often detected at night: when lying flat, the weakened diaphragm can no longer adequately expand the lungs, leading to a buildup of carbon dioxide in the blood and drops in oxygen levels during sleep.1PubMed Central. Diaphragmatic Neurophysiology and Respiratory Markers in ALS Morning headaches, daytime drowsiness, and fragmented sleep are common clues that respiratory function is declining before it becomes obvious during waking hours.
Large studies of ALS deaths consistently find respiratory failure at the top of the list. A U.S. analysis of over 25,000 death certificates found respiratory failure co-occurring with ALS in about a quarter of cases, followed by cardiovascular disease, pneumonia, and aspiration-related lung inflammation.2PubMed Central. Causes of death among United States decedents with ALS – Section: Results A German registry painted an even starker picture, with respiratory failure accounting for roughly 60% of deaths, followed by pneumonia at about 9%.3PubMed. Causes of death in amyotrophic lateral sclerosis – Section: Results An autopsy-based study found that bronchopneumonia and pneumonia were the dominant findings at death, with heart failure accounting for about 10% and pulmonary embolism about 6%.4PubMed. Causes of death in a post-mortem series of ALS patients The variation in these numbers reflects different methods of counting causes of death, but the pattern is consistent: the lungs give out first in most people with ALS.
What Happens to Swallowing and Nutrition
Difficulty swallowing, known clinically as dysphagia, affects more than two-thirds of people with ALS at some point, regardless of whether their disease started in the limbs or the muscles of the mouth and throat.5PubMed Central. Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis In the final stages, swallowing becomes increasingly dangerous. Food and saliva can enter the airway instead of the stomach, a phenomenon called aspiration, which is a major driver of the pneumonia that kills many ALS patients.
When swallowing deteriorates to a certain point, many patients consider a feeding tube placed directly into the stomach. This can maintain nutrition and hydration, but it doesn’t eliminate aspiration risk entirely because saliva still accumulates in the throat. Weight loss, which may already be underway from earlier in the disease, accelerates in the final stages. ALS is associated with broader metabolic disruptions, including a higher-than-expected resting energy expenditure. Essentially, the body burns more calories than you would predict for someone who is immobile.6The Lancet Neurology. Energy metabolism in amyotrophic lateral sclerosis This hypermetabolism, combined with the inability to eat enough, contributes to the severe wasting seen in advanced disease. In the German registry data, terminal cachexia (extreme wasting) was listed as the cause of death in about 6% of cases.3PubMed. Causes of death in amyotrophic lateral sclerosis – Section: Results
The Locked-In State and What Remains
The trajectory of physical decline in late-stage ALS leads some patients toward a locked-in state, where the mind remains active but voluntary movement is almost entirely gone. The last voluntary movements to survive are typically eye movements. This is not coincidence: the motor neurons that control eye muscles are biologically distinct from those supplying limbs and the trunk, and they resist degeneration throughout the disease.7PubMed Central. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis For many patients in the final stages, eye tracking becomes the sole means of communication, allowing them to select letters on a screen or answer yes-or-no questions.
Even eye movements eventually slow and become limited in some patients. A physiological study of the transition from a locked-in to a completely locked-in state documented the loss of facial muscle activity and external sphincter control while eye movements persisted but became slow and brief. Once even those faded, brain-based electrical responses to sound and passive limb movement could still be detected, though responses to touch on the skin were absent.8Clinical Neurophysiology. Transition from the locked in to the completely locked-in state – Section: Results The completely locked-in state, where no voluntary output remains, is mercifully rare, but it underscores why advance planning for communication and end-of-life preferences is so urgent.
One cohort study of patients on long-term ventilation found that by the time they were approaching end of life, their functional scores were profoundly low (averaging about 5.6 out of 48 on a standard ALS scale), and about 41% had lost even eye movement.9PubMed. Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation
Cognitive and Behavioral Shifts
ALS is no longer considered a purely motor disease. Cognitive and behavioral changes become more frequent as the disease progresses, and by the end stage, only a small percentage of patients are entirely free of neuropsychological impairment.10PubMed Central. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS The kinds of thinking affected tend to involve executive functions (planning, mental flexibility), language, and verbal fluency rather than memory or spatial reasoning, at least initially. Behavioral changes, such as apathy, loss of empathy, and disinhibition, also become more common with advancing disease stage.
A population-based study of nearly 800 patients found that the proportion meeting criteria for ALS with frontotemporal dementia rose from about 16% in early disease to over 44% in the most advanced stage.11PubMed Central. Cognitive impairment across ALS clinical stages in a population-based cohort – Section: RESULTS This matters enormously for end-of-life planning. If cognitive decline is going to affect the ability to make complex decisions, those decisions ideally need to happen while the person can still fully participate. Families are sometimes blindsided by personality changes or difficulty understanding options, and these changes can strain relationships already under enormous pressure.
Pain, Autonomic Trouble, and Other Non-Motor Symptoms
There is a persistent misconception that ALS is painless because it primarily affects motor neurons. In reality, pain is common, with reported prevalence ranging anywhere from 15% to 85% of patients depending on how it is measured.12PubMed Central. Amyotrophic Lateral Sclerosis and Pain – Section: Abstract Pain can occur at any stage and in any part of the body without a predictable pattern.13PubMed Central. Pain in amyotrophic lateral sclerosis – Section: Abstract In the final stages, when patients are immobile for extended periods, secondary pain from joint stiffness, contractures, and pressure from prolonged bed rest tends to worsen. Muscle cramps and spasticity also contribute.
The autonomic nervous system, which controls heart rate, blood pressure, digestion, and other involuntary functions, also takes damage. Cardiac autonomic dysfunction is increasingly recognized as a meaningful part of the disease burden, showing up as abnormal heart rate variability, excessive sympathetic nervous system activity, and prolonged electrical intervals in the heart.14PubMed. Cardiac Autonomic Dysfunction and Sudden Cardiac Death in Amyotrophic Lateral Sclerosis These cardiac changes are not just incidental findings on a monitor. A study examining the terminal stage specifically found significantly prolonged QTc intervals compared to the early stage, and two patients who experienced sudden cardiac arrest had the longest intervals and the most severe loss of sympathetic neurons in the spinal cord.15PubMed. Sympathetic disturbances increase risk of sudden cardiac arrest in sporadic ALS Cardiac MRI research has also identified structural heart muscle defects in ALS patients that may result from sustained sympathetic overactivity, potentially explaining why sudden cardiac death is one of the leading causes of death after respiratory insufficiency.16PubMed Central. Cardiac Findings in Amyotrophic Lateral Sclerosis – Section: Discussion
Ventilation Decisions and What They Mean for Survival
When breathing weakens, non-invasive ventilation (a mask-based device, most commonly bilevel positive airway pressure) is the first-line support. It helps maintain gas exchange and can improve both sleep quality and daytime energy. Eventually, non-invasive ventilation may not be enough, and the question of tracheostomy-based invasive ventilation arises. This is one of the most consequential decisions in the ALS trajectory.
A large German cohort study found that patients using non-invasive ventilation had a median survival of about 41 months from diagnosis, while those on invasive tracheostomy ventilation survived a median of about 82 months, compared to roughly 34 months in patients who used no ventilatory support at all.17PubMed. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis Those numbers can look compelling, but they require context. Tracheostomy ventilation has been associated with a lower quality of life and a higher likelihood of requiring institutional care compared to non-invasive ventilation.18Swiss Medical Weekly. Is tracheostomy still an option in amyotrophic lateral sclerosis? – Section: Results Many patients on long-term tracheostomy ventilation progress to a state where they are entirely dependent on the ventilator around the clock, which raises profound questions about what the extended survival looks like from the patient’s perspective.
Rates of tracheostomy use vary dramatically across countries and cultures. In Japan, tracheostomy ventilation is more common; in many European countries and North America, it is chosen by only a small minority of patients. The decision is deeply personal and depends on the patient’s values, the availability of home care support, and the anticipated trajectory of cognitive function.
Palliative Care and Managing Breathlessness
Regardless of ventilation decisions, palliative care becomes central in the final stages. Breathlessness (dyspnea) is one of the most distressing symptoms, and there is good evidence that opioids are safe and effective for managing it. A systematic review found that opioids improved breathlessness in ALS patients with manageable side effects, primarily constipation, and that careful dose titration against symptoms rarely led to dangerous respiratory depression.19PubMed Central. Optimizing breathlessness management in amyotrophic lateral sclerosis – Section: Discussion This is worth emphasizing because families and even some clinicians fear that opioids will hasten death in a person whose breathing is already compromised. The evidence does not support that fear when doses are appropriately managed.
For patients on long-term ventilation who decide to discontinue it, palliative protocols have been studied in some detail. Whether a patient can tolerate any time off the ventilator determines the approach. Patients with some ventilator-free tolerance may receive increased symptom control medications (opioids and sedatives) without the explicit goal of sedation, and the time from ventilator disconnection to death in one cohort averaged about 32 hours. For patients with no ventilator-free tolerance, continuous deep sedation is initiated before the ventilator is removed, and death typically follows within minutes.9PubMed. Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation A separate evaluation of ventilation withdrawal practices found that about 89% of patients received opioid or sedative medication at the initiation of withdrawal. Most patients on tracheostomy ventilation died within 30 minutes of removal, while the time after non-invasive ventilation withdrawal varied widely, from under 15 minutes to over 54 hours.20PubMed. Mechanical ventilation withdrawal in motor neuron disease
Communication in the Late Stages
Losing the ability to speak and eventually to type or gesture creates an isolation that is hard to overstate. Eye-tracking devices are currently the most widely used technology for patients who retain eye movement. For those who lose even that, brain-computer interfaces are an active area of research. These systems detect electrical signals from the brain and translate them into text or cursor movements.
The most dramatic demonstration to date involved a fully implanted brain-computer interface in a locked-in ALS patient, which provided autonomous communication that supplemented and sometimes replaced the patient’s eye-tracking device.21PubMed Central. Fully Implanted Brain-Computer Interface in a Locked-In Patient with ALS Another study showed that two participants, one with ALS and one with locked-in syndrome from a different cause, used a simpler brain signal-based system for months without needing recalibration, achieving spelling rates of roughly 3 to 7 correct characters per minute.22PubMed Central. Stable long-term BCI-enabled communication in ALS and locked-in syndrome using LFP signals That is slow, but for someone who has no other way to form a sentence, it is transformative. Still, these systems remain largely experimental, and several technical and practical challenges must be solved before they become routine clinical tools.23PubMed Central. Brain-computer interfaces for amyotrophic lateral sclerosis
Medical Assistance in Dying
In jurisdictions where it is legal, medical assistance in dying (MAiD) has become a meaningful part of the ALS end-of-life landscape. A Canadian clinic found that about 22% of their ALS patients chose MAiD.24PubMed. Medical Assistance in Dying in ALS – Section: RESULTS A California study found that the most common motivations were concerns about current and future suffering, loss of autonomy and enjoyable activities, and the desire to retain control over the timing and manner of death. Interestingly, “persistent and uncontrollable pain” was a less common documented reason than the broader concerns about autonomy and suffering.25PubMed Central. Characteristics and Motivations of People With Amyotrophic Lateral Sclerosis Who Pursue Medical Aid in Dying in California – Section: Results The Canadian data also showed that patients who chose MAiD were less likely to have had a feeding tube placed and died at home more often than those who did not choose it.
These findings suggest that for many patients, the decision is less about escaping physical agony and more about maintaining agency in the face of progressive dependency. The timing is also telling: patients who chose MAiD in the Canadian cohort had a shorter survival from diagnosis, not because they were sicker faster, but because they elected to die before the most advanced stages arrived.
The Caregiver Burden
The final stages of ALS are not experienced by the patient alone. Caregivers, typically family members, face escalating physical and emotional demands. Interviews with caregivers of severely impaired ALS patients revealed themes of helplessness, difficulty adapting to constant life changes, hopelessness in the face of the prognosis, and a need for diverse forms of support that often went unmet.26Neuroethics. Caregivers of ALS Patients: Their Experiences and Needs As the patient’s functional status declines, caregiver tasks expand to include operating ventilators, managing feeding tubes, repositioning to prevent skin breakdown, suctioning airways, and interpreting increasingly subtle communication signals. The toll is physical, financial, and psychological, and it intensifies as the disease progresses toward its end.
A Peculiar Resilience Against Bedsores
One of the stranger observations in ALS research is that patients develop bedsores (pressure ulcers) far less often than you would expect for people who are immobile for extended periods. Skin biopsies from the sacral region, one of the most vulnerable areas for pressure sores, revealed that ALS patients have denser, more tightly packed collagen fibers in their skin compared to controls, and that this density increases with the duration of illness.27Journal of the Neurological Sciences. Increased dermal collagen density in amyotrophic lateral sclerosis The increased collagen density may protect against pressure-induced loss of blood flow, which is the primary mechanism behind bedsore formation. This is a small consolation, but for caregivers managing an immobile patient, the relative rarity of severe bedsores is one less crisis to manage.
Biomarkers and Predicting the Pace of Decline
ALS is famously heterogeneous. Some people survive for a decade or more, while others die within a year of diagnosis. The pace at which someone enters and moves through the final stages varies enormously, and there has been intense interest in blood-based biomarkers that can predict this trajectory. Neurofilament light chain, a protein released into the blood and spinal fluid when nerve cells are damaged, has emerged as the most promising marker. Higher levels correlate with faster disease progression and shorter survival.28JAMA Neurology. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis – Section: Results Patients with rapidly declining lung function also tend to have higher neurofilament levels.29PubMed Central. FVC-DiP correlates with neurofilament light chain levels in serum and cerebrospinal fluid in patients with ALS – Section: RESULTS
On the flip side, patients with low neurofilament levels and long disease duration tend to have a more favorable prognosis, and in patients on long-term ventilation, levels may decrease over time, possibly reflecting a reduced rate of ongoing nerve damage or simply that there is less neural tissue left to shed the protein.30PubMed. Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis While not yet part of routine clinical decision-making everywhere, neurofilament measurements are increasingly being used to help patients and families understand what timeline they are likely facing and to inform decisions about ventilation, feeding tubes, and advance directives.
Survival Has Improved, but the Disease Has Not Changed
One piece of context worth understanding is that survival in ALS has gotten somewhat longer over the past few decades, but this improvement comes from better supportive care rather than any change in the underlying biology. A study comparing patients diagnosed between 1999 and 2004 with those diagnosed between 1984 and 1999 found that median survival from symptom onset increased from about 3.2 years to about 4.3 years.31JAMA Neurology. Slower Disease Progression and Prolonged Survival in Contemporary Patients With Amyotrophic Lateral Sclerosis – Section: Results An analysis of placebo groups in clinical trials confirmed that survival improved over time even as the rate of functional decline measured by standard scales stayed essentially the same.32PubMed. The natural history of ALS is changing – Section: Abstract In other words, the disease still destroys motor neurons at the same rate, but multidisciplinary care, ventilation support, nutritional management, and palliative interventions help people live longer with that destruction. The final stages look largely the same as they did decades ago, but patients arrive there more slowly and with better symptom control along the way.